Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently published a list of Jim Cramer Discusses These 13 Stocks & Rejects The AI PC Super Cycle. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against ...

after pleading guilty to one count of being a Serious Violent Felon in Possession of a Firearm and one count of Dealing in a Narcotic Drug, both Level 4 felonies. Johnson’s sentence includes ...

Johnson & Johnson's Q4 2024 earnings missed ... JNJ's long-term growth strategy focuses on high-growth markets and promising pipeline products. JNJ's MedTech division showed strong performance ...

House Speaker Mike Johnson says former President Joe Biden’s last-minute pardons of his family members were "shocking" and "disgusting." "It was shocking. I mean, it was shocking what President ...

Johnson & Johnson (JNJ ... as generics launch for its blockbuster anti-inflammatory arthritis drug Stelara. The drug is also now facing pricing pressures from a newly negotiated price with ...

Overall, Johnson & Johnson ... property against generic competition. This quarter, sales in its Innovative Medicine segment grew by 4.4% year over year, led by products like Darzalex in oncology ...

Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02 ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant depression. This landmark decision ...